Myogenesis Explained: How Myoblasts Become Muscle Fibres, and How Labs Model It

Myogenesis is the process by which myoblasts, committed muscle precursor cells, stop dividing, fuse with one another and mature into the multinucleated fibres of skeletal muscle. It runs in the embryo, runs again when adult muscle regenerates, and is modelled in the laboratory with cultured myoblasts such as the mouse C2C12 line. Knowing the program step by step is what makes a differentiation assay interpretable.

This guide covers the myogenic regulatory factors, fusion and maturation, the signals that steer myoblast differentiation, the main in-vitro models and their readouts and pitfalls, and what research peptides have shown in myoblast cultures, with the evidence level stated for each.

What myogenesis is: embryonic and adult

Myogenesis is the formation of skeletal muscle fibres from myogenic precursor cells. A precursor commits to the muscle lineage as a myoblast, which still divides; a myoblast that leaves the cell cycle becomes a myocyte; myocytes fuse into myotubes, cells with many nuclei; and myotubes mature into myofibres filled with myofibrils.

In the embryo

Skeletal muscles of the body arise from somites, transient embryonic structures derived from presomitic mesoderm. The dermomyotome, a somite compartment, gives rise to skeletal muscle, brown fat and the dermis of the back, so brown adipose tissue shares an origin with muscle. The first postmitotic muscle cells are the myocytes of the primary myotome. Pax3-positive cells from the central dermomyotome then populate the myotome, and Pax7-positive progenitors later form secondary, fetal fibres, using the primary fibres as a scaffold.

In adult muscle

Developmental myosins disappear from most skeletal muscles in early postnatal life as adult fast myosins rise, but the program returns during regeneration, which is mediated by satellite cells under the basal lamina of each fibre. They are activated, proliferate and fuse to form new fibres, which re-express embryonic and neonatal myosin heavy chains two to three days after injury. This guide follows the differentiation program rather than satellite-cell biology.

The myogenic regulatory factors

The myogenic regulatory factors (MRFs) are Myf5, MyoD, MRF4 (also called Myf6) and myogenin. Each carries a basic helix-loop-helix (bHLH) motif. MyoD pairs with the nearly ubiquitous E-proteins, and the pair binds E-boxes, DNA sites with the core sequence CANNTG; MEF2 factors cooperate with MyoD to activate subsets of muscle genes.

The idea of a master switch came from fibroblasts. Mouse 10T1/2 fibroblasts exposed to the demethylating agent 5-azacytidine gave rise to myogenic cells, and that system was used to clone the determination gene Myod1. In 1987 Robert Davis, Harold Weintraub and Andrew Lassar at the Fred Hutchinson Cancer Research Center in Seattle showed that one transfected cDNA, MyoD, converts fibroblasts to myoblasts. Mouse genetics then sorted out the roles. Mice lacking both MyoD and Myf5 formed no skeletal muscle, a 1993 result from Michael Rudnicki at McMaster University in Hamilton, Ontario, with Rudolf Jaenisch’s group at the Whitehead Institute and colleagues in Braunschweig. Myogenin acts downstream of both and, in the embryo, controls the terminal differentiation of myoblasts into myocytes. MRF4 blurs the hierarchy: in 2004, mice lacking Myf5 and MyoD still formed skeletal muscle if MRF4 expression was intact.

From myoblast to myotube: cell-cycle exit, fusion and maturation

Leaving the cell cycle

Myocytes do not divide, and cells that fail to leave the cycle differentiate poorly. C2C12 cells taken through 58 population doublings kept more cells in S phase and fewer in G1, expressed less MyoD and myogenin, and showed reduced differentiation both by morphology and by creatine kinase activity.

Alignment and fusion

In C2C12 cultures followed by light and electron microscopy, fusiform or star-shaped myoblasts became elongated, confluent cells and then long, multinucleated myotubes. Fusion itself depends on two small muscle-specific proteins. Myomaker, described in 2013 by Douglas Millay, Eric Olson and colleagues, is a membrane protein that appears on the myoblast surface during fusion and is downregulated afterwards. Mice without it die around birth with no multinucleated fibres, and fibroblasts made to express it fuse with myoblasts, an activity that needs the actin cytoskeleton. Myomerger, reported in 2017, is skeletal-muscle-specific and 84 amino acids long in its short form. Together the two proteins make otherwise non-fusogenic cells such as fibroblasts fuse, and mice lacking myomerger have very few muscle fibres.

Maturation and sarcomere assembly

Fusion and contractile assembly are separable: myocytes lacking myomerger still differentiate and build organized sarcomeres, the repeating contractile units of muscle, but cannot fuse. In C2C12 cultures, sarcomeric actin and myosin are present even in undifferentiated myoblasts, and sarcomeres and myofibrils appear about five days after differentiation is induced. Myosin isoforms follow a developmental sequence: C2C12 cells moved to low-serum medium first express embryonic, neonatal and slow myosin heavy chains, which then decline while adult fast isoforms rise, as in rodent fast muscle. Cultured muscle still stays young: engineered bundles of human myotubes produced tetanic force similar to fetal human muscle, about an order of magnitude below adult values.

Signals that promote or restrain myoblast differentiation

The studies below were done mainly in cultured muscle cells, where each signal can be added or blocked on its own.

IGF-1: two pathways, two outcomes

Insulin-like growth factors stimulate both proliferation and differentiation of myoblasts. In rat L6A1 myoblasts, blocking the MAP kinase pathway suppressed IGF-stimulated proliferation but enhanced differentiation, while blocking PI3K or p70S6 kinase abolished IGF-stimulated differentiation. See what IGF-1 is, our MAPK/ERK pathway guide and our mTOR explainer.

Myostatin: a Smad3 brake

Myostatin is a negative regulator of myogenesis. Added to C2C12 myoblasts in low-serum culture, it reversibly blocked differentiation and lowered MyoD, Myf5, myogenin and p21; extra MyoD did not rescue the block, which ran through Smad3. The authors linked this to the hyperplasia and hypertrophy of animals lacking functional myostatin.

Notch: holding the program back

Myf5 and Notch transcripts are both present in presomitic mesoderm before muscle commitment, yet that tissue does not make muscle, which pointed to a built-in brake. The intracellular domain of mouse Notch proved to be a constitutively active repressor of myogenesis in cultured cells and frog embryos, aimed at the bHLH region of MyoD.

Wnt/β-catenin: several jobs

In C2C12 cells and primary mouse myoblasts, blocking Wnt/β-catenin signalling during proliferation slowed division through cyclin A2 and Cdc25c, blocking it during differentiation prevented fusion through Fermt2, and blocking it in well-differentiated cultures disrupted the cadherin/β-catenin/actin complex that maintains myofibre structure.

In-vitro models of myogenesis compared

No culture reproduces adult human muscle, so the model is part of the experimental design. A 2020 comparison of rat L6, mouse C2C12 and primary human skeletal muscle cells found a great degree of heterogeneity in their transcriptomes and metabolism, and its authors recommend choosing the model to fit the question.

The C2C12 subclone was produced by H. Blau and colleagues; L6 was established by David Yaffe and Sara Neuman. A 2015 serum-free method took mouse and human pluripotent cells through a presomitic-mesoderm-like stage, without transgenes or cell sorting, to striated, contractile fibres, and fibres from dystrophin-deficient mdx mouse cells showed the abnormal branching seen in Duchenne muscular dystrophy. Human myobundles, cast in a fibrin-based hydrogel, reported calcium transients and responded to statins and chloroquine in ways that mimic clinical responses.

How differentiation is induced and read out

Myoblasts are expanded in growth medium below confluence, then moved to low-serum medium, which induces differentiation. Readouts then follow the program:

• Myosin heavy chain staining. Immunostaining for myosin heavy chain, with a nuclear counterstain, marks differentiated cells and shows which nuclei sit inside myotubes.
• Fusion index. The share of all nuclei that lie within myotubes. Definitions vary: one 2021 Fiji tool counts only myosin-positive cells with three or more nuclei, and its authors note that manual counting is extremely time-consuming and varies between researchers.
• Markers. qRT-PCR and western blots for MyoD, myogenin and myosin isoforms track the program over days, and creatine kinase activity gives a biochemical index.

Common pitfalls in myoblast culture

• Passage number. C2C12 cells after 58 population doublings also expressed less IGF-I and more IGFBP5, so compare cultures at matched doublings.
• Confluence. ATCC warns that letting C2C12 stock cultures become confluent depletes the myoblastic population.
• Mycoplasma. A survey of 9,395 RNA-seq samples from 884 series found about 11% of series contaminated, with 61 host genes whose expression tracked mycoplasma reads, a direct threat to gene-expression readouts.
• Endotoxin. C2C12 myoblasts raise TNF-α and IL-6 mRNA in response to bacterial lipopolysaccharide, so a contaminated reagent adds an inflammatory signal to the assay; see endotoxin in research peptides.
• Single-model conclusions. An effect in C2C12 may not appear in L6 or human cells. Pair each readout with a vehicle control and, for peptides, a scrambled-sequence control.

Research peptides in myoblast and myotube studies

Research peptides appear in myoblast work as receptor tools and as compounds whose effects on differentiation are under study. Everything below is cell-culture evidence.

IGF-1 LR3. Long R3 IGF-I replaces glutamate at position 3 of IGF-I with arginine and adds an N-terminal extension derived from porcine growth hormone. In the 1992 paper describing the analogue family, the analogues were more potent than IGF-I at stimulating DNA synthesis and inhibiting protein breakdown in L6 myoblasts, but Long R3 IGF-I was less potent than IGF-I in chick embryo fibroblasts, which secrete no detectable IGF-binding proteins. The authors attributed the gain mainly to weaker interaction with binding proteins, which makes LR3 a tool for probing IGF-1 receptor signalling in cultures whose cells make binding proteins, as C2C12 cells make IGFBP5. See our IGF-1 LR3 research guide.

MOTS-c. MOTS-c is a mitochondrial-derived peptide (see our MOTS-c guide). In a 2025 study, it increased C2C12 survival in a viability assay, lowered the proliferation marker PCNA, briefly raised ERK1/2 phosphorylation, and increased MyoD and myogenin at two and six days and embryonic myosin (Myh3) at six days; rat L6 cells shared the fall in proliferation but showed little else. That is one group’s cell-culture result, and the C2C12–L6 discordance is the practical lesson.

What’s established and what isn’t

Sourcing peptides for muscle-cell research in Canada

Myoblast assays respond to whatever is in the vial, so a wrong sequence or an inflammatory contaminant can change a differentiation readout. When buying research peptides in Canada for this work:

• Match the certificate to the batch: identity by mass spectrometry, purity by HPLC and a batch number that matches the vial; see our COA guide and HPLC testing guide.
• Ask about endotoxin before a peptide goes onto cells that respond to lipopolysaccharide, as C2C12 myoblasts do.
• Store lyophilized material cold, dry and dark; see what lyophilized means and our peptide storage guide.

For a wider overview, see research peptides in Canada.

IGF-1 LR3IGF-I analogue with weak binding-protein interaction; L6 myoblast dataView product MOTS-cMitochondrial-derived peptide compared in C2C12 and L6 cellsView product

Frequently asked questions